Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Cell and Gene Therapy Insights 2023; 9(4), 465;

DOI:10.18609/cgti.2023.068

Published: 19 May 2023
FastFacts
Tareq Jaber


Watch the video or view the poster for:

  • An evaluation of process steps that can be utilized for gene therapy products
  • A better understanding of how to apply prior knowledge to your viral clearance process
  • A step-by-step overview of performing platform validation